HK1080092A1 - Vegf antagonists for the treatment of diabetes - Google Patents

Vegf antagonists for the treatment of diabetes

Info

Publication number
HK1080092A1
HK1080092A1 HK06102834A HK06102834A HK1080092A1 HK 1080092 A1 HK1080092 A1 HK 1080092A1 HK 06102834 A HK06102834 A HK 06102834A HK 06102834 A HK06102834 A HK 06102834A HK 1080092 A1 HK1080092 A1 HK 1080092A1
Authority
HK
Hong Kong
Prior art keywords
vegf
diabetes
treatment
vegf antagonists
blocking
Prior art date
Application number
HK06102834A
Other languages
English (en)
Inventor
Mark W Sleeman
Stanley J Wiegand
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of HK1080092A1 publication Critical patent/HK1080092A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK06102834A 2003-03-28 2006-03-03 Vegf antagonists for the treatment of diabetes HK1080092A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45879003P 2003-03-28 2003-03-28
PCT/US2004/009246 WO2004087206A2 (en) 2003-03-28 2004-03-26 Methods of treating diabetes by blocking vegf-mediated activity

Publications (1)

Publication Number Publication Date
HK1080092A1 true HK1080092A1 (en) 2006-04-21

Family

ID=33131825

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06102834A HK1080092A1 (en) 2003-03-28 2006-03-03 Vegf antagonists for the treatment of diabetes

Country Status (17)

Country Link
US (1) US7052691B2 (es)
EP (1) EP1608685B1 (es)
JP (2) JP4730909B2 (es)
AT (1) ATE354592T1 (es)
AU (1) AU2004226417B2 (es)
BR (1) BRPI0408749B1 (es)
CA (1) CA2519787C (es)
CY (1) CY1106530T1 (es)
DE (1) DE602004004883T2 (es)
DK (1) DK1608685T3 (es)
ES (1) ES2278333T3 (es)
HK (1) HK1080092A1 (es)
MX (1) MXPA05008972A (es)
PL (1) PL1608685T3 (es)
PT (1) PT1608685E (es)
SI (1) SI1608685T1 (es)
WO (1) WO2004087206A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1997386B (zh) * 2004-07-30 2012-05-30 瑞泽恩制药公司 通过阻断vegf介导的活性来治疗i型糖尿病的方法
CN101141975B (zh) 2005-03-25 2012-05-23 瑞泽恩制药公司 Vegf拮抗剂制剂
KR101406811B1 (ko) 2006-06-16 2014-06-12 리제너론 파마슈티칼스 인코포레이티드 유리체내 투여에 적당한 ｖｅｇｆ 길항제 제형
ES2345596B1 (es) * 2009-03-26 2011-07-13 Fundacion Progreso Y Salud Composicion para la prevencion o el tratamiento de la diabetes mellitus.
US20100330098A1 (en) * 2009-06-29 2010-12-30 Kuo Calvin J Methods to regulate glucose metabolism
KR20210030510A (ko) 2011-01-13 2021-03-17 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
ES2648809T3 (es) 2014-01-25 2018-01-08 Chengdu Kanghong Biotechnologies Co., Ltd. Proteína de fusión que inhibe la angiogénesis o el crecimiento y uso de esta
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3170005B1 (en) 2014-07-18 2019-04-10 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
CN108712911A (zh) 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
ITUB20169928A1 (it) * 2016-01-12 2017-07-12 Medical And Biotechnological Services In Sigla M B S Srl Formulazioni farmaceutiche per il trattamento del diabete
JP2022553640A (ja) 2019-10-10 2022-12-26 コディアック サイエンシーズ インコーポレイテッド 眼障害を処置する方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9410533D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd In situ hybridisation and immuno-Chemical localisation of a growth factor
JP4926320B2 (ja) * 1999-04-28 2012-05-09 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Ｖｅｇｆの選択的阻害による癌処置のための組成物および方法
ES2319305T3 (es) * 1999-06-08 2009-05-06 Regeneron Pharmaceuticals, Inc. Quimeras del receptor del vegf para el tratamiento de trastornos oculares caracterizados por la permeabilidad vascular.
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases

Also Published As

Publication number Publication date
DE602004004883D1 (de) 2007-04-05
WO2004087206A2 (en) 2004-10-14
US20040213787A1 (en) 2004-10-28
MXPA05008972A (es) 2005-11-04
EP1608685B1 (en) 2007-02-21
SI1608685T1 (sl) 2007-08-31
PL1608685T3 (pl) 2007-07-31
BRPI0408749A (pt) 2006-03-28
EP1608685A2 (en) 2005-12-28
WO2004087206A3 (en) 2004-12-16
DE602004004883T2 (de) 2007-11-15
BRPI0408749B1 (pt) 2016-10-04
CA2519787A1 (en) 2004-10-14
JP2011037894A (ja) 2011-02-24
JP2006521397A (ja) 2006-09-21
CY1106530T1 (el) 2012-01-25
JP4730909B2 (ja) 2011-07-20
ATE354592T1 (de) 2007-03-15
AU2004226417B2 (en) 2009-01-22
US7052691B2 (en) 2006-05-30
AU2004226417A1 (en) 2004-10-14
CA2519787C (en) 2012-06-05
ES2278333T3 (es) 2007-08-01
DK1608685T3 (da) 2007-06-11
PT1608685E (pt) 2007-05-31

Similar Documents

Publication Publication Date Title
HK1080092A1 (en) Vegf antagonists for the treatment of diabetes
HK1105167A1 (en) Methods of treating type i diabetes by blocking vegf-mediated activity
DE60210093D1 (de) Beta-amino-tetrahydroimidazo(1,2-a)pyrazine und -tetrahydrotriazolo(4,3-a)pyrazine als dipeptidyl peptidase inhibitoren zur behandlung oder prevention von diabetes
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
MXPA05010819A (es) Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
WO2006023649A3 (en) Treatment of severe multiple sclerosis
ATE435015T1 (de) Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
MY151032A (en) Treatment of tnf? related disorders
WO2004105757A3 (en) Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
EA200801118A1 (ru) Способ ингибирования flt3 киназы
WO2005107726A3 (en) Method for the treatment of back pain
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
TW200716673A (en) Use of TNF &ahr; inhibitor for treatment of erosive polyarthritis
WO2003105840A3 (en) SPHINGOSINE KINASE INHIBITORS
WO2004084943A8 (en) Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
WO2007073497A3 (en) Calcium channel antagonists
MXPA05001649A (es) Uso de compuestos antagonistas del cgrp para tratamiento de la psoriasis.
ATE555803T1 (de) Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
WO2006060787A3 (en) Delaying or preventing onset of multiple sclerosis
WO2004009773A3 (en) Methods and compositions for activating or inhibiting vegf-d and vegf-c
WO2006016192A3 (en) Combination therapy with nk3 receptor antagonists for the treatment of schizophrenia
DE60214019D1 (de) Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren
ATE533769T1 (de) Als kinaseinhibitoren geeignete pyrrolotriazinverbindungen
TW200603792A (en) Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
DE602004022423D1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190326